’s partner Generex Biotechnology Corporation has filed for a trademark for its li-Key vaccine and patent for its Ii-Key-SARS-CoV-2 vaccine.
In a statement issued on Thursday, Bintai Kinden said the Ii-Key vaccine was designed to be a complete vaccine for the Covid-19.
“The technology offers the safest and best route for the rapid development of a Covid-19 vaccine, ” it said.
It explained the complete vaccine is designed to regulate the immune system to provide a targeted, neutralising antibody response.
Bintai Kinden managing director Ong Choon Lui said Generex’s Covid-19 vaccine was based on the results of the ex-vivo human studies. It will be formulated for phases one and two clinical trials.
IF 2020 is the year of rubber glove manufacturers and technology-related counters, penny stocks deserve at least a notable mention.
The penny stock fever on the local bourse has not been seen for at least 20 years since the dotcom bubble burst.
The eye-popping share price rally lured long-absent retail investors to the stock market and that, in turn, lifted the daily trading volume to a record high of 27.8 billion shares on Aug 11.
At the height of the penny stock fever in August, share prices hitting limit up were not a rare sight. On Aug 7, 12 stocks hit limit up, including HLT Global Bhd, LKL International Bhd and ES Ceramics Technology Bhd. These three were below 20 at the start of 2020.
KUALA LUMPUR: Bintai Kinden Corp Bhd’s partner, Generex Biotechnology Corp has filed for a trademark for its li-Key vaccine, to be known as “The Compl.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development .
Generex Biotechnology Corp.December 31, 2020 GMT
The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS)
Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply
Ii-Key epitopes selected that elicit both CD4+ T Helper cell (Th1) and CD8+ responses that are necessary for long-term immune memory
Ii-Key epitopes elicited no Th2 T cell responses that have been linked to antibody dependent enhancement of disease and cytokine storm
Home / Top News / Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™
The trademark application can be found at USPTO.gov by searching “Complete Vaccine” in the Trademark Electronic Search System (TESS)
Ii-Key-SARS-CoV-2 vaccine enters GMP production for clinical supply
Ii-Key epitopes selected that elicit both CD4+ T Helper cell (Th1) and CD8+ responses that are necessary for long-term immune memory
Ii-Key epitopes elicited no Th2 T cell responses that have been linked to antibody dependent enhancement of disease and cytokine storm